Evogene price target lowered to $12 from $30 at Lake Street

Lake Street analyst Ben Klieve lowered the firm’s price target on Evogene to $12 from $30 and keeps a Buy rating on the shares. The firm lowers its target “following the post-split slide,” but notes that Q2 operating losses were narrower than expected and adds that it still believes “a major commercial catalyst looms” as it expects a steep commercial ramp for the company’s high-margin castor seed product.